Marc Tessier Lavigne Regeneron Pharmaceuticals, Inc. (REGN) insider trading activity

Marc Tessier Lavigne is Director of REGENERON PHARMACEUTICALS, INC.. Currently has a direct ownership of 2,434 shares of REGN, which is worth approximately $1.67 Million. The most recent transaction as insider was on Jan 03, 2023, when has been sold 165 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 2.43K

0% 3M change

0% 12M change

Total Value Held $1.67 Million

Marc Tessier-Lavigne Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 03 2023	BUY Grant, award, or other acquisition	-	165 Added 6.35%	2,434 Common Stock
Jan 03 2023	BUY Grant, award, or other acquisition	-	165 Added 6.35%	2,434 Common Stock
Oct 03 2022	SELL Open market or private sale	$2,593,416 $718.0 p/Share	3,612 Reduced 61.42%	2,269 Common Stock
Oct 03 2022	BUY Exercise of conversion of derivative security	$1,492,948 $413.33 p/Share	3,612 Added 38.05%	5,881 Common Stock
Sep 30 2022	SELL Open market or private sale	$2,392,744 $698.0 p/Share	3,428 Reduced 60.17%	2,269 Common Stock
Sep 30 2022	BUY Exercise of conversion of derivative security	$1,416,895 $413.33 p/Share	3,428 Added 37.57%	5,697 Common Stock
Sep 29 2022	SELL Open market or private sale	$2,637,749 $694.51 p/Share	3,798 Reduced 62.6%	2,269 Common Stock
Sep 29 2022	BUY Exercise of conversion of derivative security	$1,569,827 $413.33 p/Share	3,798 Added 38.5%	6,067 Common Stock
Mar 21 2022	SELL Open market or private sale	$5,132,910 $690.0 p/Share	7,439 Reduced 76.63%	2,269 Common Stock
Mar 21 2022	BUY Exercise of conversion of derivative security	$2,833,887 $380.95 p/Share	7,439 Added 43.38%	9,708 Common Stock
Mar 17 2022	SELL Open market or private sale	$5,324,400 $680.0 p/Share	7,830 Reduced 77.53%	2,269 Common Stock
Mar 17 2022	BUY Exercise of conversion of derivative security	$2,949,483 $376.69 p/Share	7,830 Added 43.67%	10,099 Common Stock
Mar 16 2022	SELL Open market or private sale	$2,943,675 $675.0 p/Share	4,361 Reduced 65.78%	2,269 Common Stock
Mar 16 2022	BUY Exercise of conversion of derivative security	$1,631,537 $374.12 p/Share	4,361 Added 39.68%	6,630 Common Stock
Jan 03 2022	BUY Grant, award, or other acquisition	-	191 Added 7.76%	2,269 Common Stock
Dec 09 2021	SELL Open market or private sale	$2,516,360 $665.0 p/Share	3,784 Reduced 64.55%	2,078 Common Stock
Dec 09 2021	BUY Exercise of conversion of derivative security	$1,405,378 $371.4 p/Share	3,784 Added 39.23%	5,862 Common Stock
Sep 13 2021	SELL Open market or private sale	$8,216,482 $644.43 p/Share	12,750 Reduced 85.99%	2,078 Common Stock
Sep 13 2021	BUY Exercise of conversion of derivative security	$3,489,293 $273.67 p/Share	12,750 Added 46.23%	14,828 Common Stock
Jan 04 2021	BUY Grant, award, or other acquisition	-	248 Added 10.66%	2,078 Common Stock
May 06 2020	SELL Open market or private sale	$8,465,700 $564.38 p/Share	15,000 Reduced 89.13%	1,830 Common Stock
May 06 2020	BUY Exercise of conversion of derivative security	$2,667,300 $177.82 p/Share	15,000 Added 47.13%	16,830 Common Stock
Feb 13 2020	SELL Open market or private sale	$5,705,602 $399.58 p/Share	14,279 Reduced 88.64%	1,830 Common Stock
Feb 13 2020	BUY Exercise of conversion of derivative security	$771,208 $54.01 p/Share	14,279 Added 56.24%	11,109 Common Stock

Also insider at

DNLI

Denali Therapeutics Inc. Healthcare

Director